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Introduction
============

Despite the improved survival of colorectal cancer (CRC) patients, metastatic disease still accounts for a high number of cancer-related deaths. Approximately 20% of patients present with metastatic disease at the time diagnosis \[[@r1]\]. The most common sites of CRC metastasis are the liver, lungs, and peritoneum, but there are other sites of metastasis, such as the bones, brain, and distant lymph nodes \[[@r2]-[@r5]\]. Autopsy studies have examined metastatic patterns and found that different primary cancers metastasize with different frequencies to different sites \[[@r5]\] and studies of CRC have revealed that histological subtypes influence metastatic patterns \[[@r5]\].

CRC predominantly occurs in the elderly population, and its incidence and mortality are expected to increase in this group \[[@r6]\]. Approximately 110,000 new cases of CRC were diagnosed in 2008 in Japan, and patients aged \>65 years accounted for \>70% of them \[[@r7]\]. However, among the patient population with distant metastasis of CRC, survival differences may depend on the site of the metastasis and the number of sites \[[@r8]-[@r10]\]. Little is known about the metastasis of this disease to different sites in different age groups \[[@r8],[@r9],[@r11],[@r12]\].

Previous studies have provided evidence that the current combination chemotherapy regimens for metastatic colorectal cancer (mCRC) is tolerable for older persons with similar treatment benefits compared to younger patients \[[@r11]\]. However, the probability of older patients with mCRC being enrolled in clinical trials or receiving surgery is low \[[@r13]\] because older patients tend to be in poor physical condition \[[@r13]\].

This study used data from the Surveillance, Epidemiology, and End Results (SEER) cancer-registry program to identify individuals diagnosed with mCRC from 2010 to 2014 with the intent to gain insight into the relevance of age in the metastatic patterns of CRC in this population. Knowledge of metastatic distributions and survival differences among the age groups may help researchers devise clinical trials, especially, to make determinations regarding curative-intent interventions.

RESULTS
=======

Demographic and clinical characteristics of patients with metastatic colorectal cancer by age group
---------------------------------------------------------------------------------------------------

Overall, 30,333 patients diagnosed with mCRC were included in our study, among which 4,309 (14.2%) were younger than 50 years old, 14,383 (47.2%) were between 50 and 69 years old, and 11,641 (38.4%) were older than 69 years old, they were defined as the younger (\<50), middle-aged (50-69), and older groups (\>69) respectively. There were 19,717 patients died at the end of the study and included 14,911 patients died from colorectal cancer. The percentage of deaths was 51.4% (2,215/4,309), 59.9% (8,615/14,383), and 76.3% (8,887/11,641) in the younger, middle-aged, and older groups, respectively. More detailed information about the age categories are presented in [Table 1](#t1){ref-type="table"}.

###### Characteristics of patients with colorectal cancer with distant metastasis by age group.

  ---------------------------- ----------- ---------------- -------- ----------------- -------- ---------------- ------ -------------
  **Patient characteristic**   **Total**   **\<50 years**            **50-69 years**            **\>69 years**          **P value**
  **No**                       **No**      **%**            **No**   **%**             **No**   **%**                   
  **Sex**                                                                                                               \<0.001
  Male                         16,616      2,350            54.5     8,455             58.8     5,811            49.9   
  Female                       13,717      1,959            45.5     5,928             41.2     5,830            50.1   
  **Married**                                                                                                           \<0.001
  Unmarried                    13,923      1,859            43.1     6,243             43.4     5,821            50     
  Married                      14,864      2,235            51.9     7,381             51.3     5,248            45.1   
  Unknown                      1,546       215              5        759               5.3      572              4.9    
  **Race**                                                                                                              \<0.001
  Black                        19,9130     2,402            55.7     9,052             62.9     8,456            72.6   
  White                        4,435       684              15.9     2,430             16.9     1,321            8.3    
  Hispanic                                 750              17.4     1,648             11.5     982              8.4    
  Asian/Pacific Islander       3,380       413              9.6      1,100             7.6      806              6.9    
  Native American              2,319       47               1.1      119               0.8      66               0.6    
  Unknown                      232         13               0.3      34                0.2      10               0.1    
  **Surgery**                                                                                                           \<0.001
  No                           14,127      1,750            40.6     6,458             44.9     5,919            50.8   
  Yes                          16,139      2,553            59.2     7,897             54.9     5,689            48.9   
  Unknown                      67          6                0.1      28                0.2      33               0.3    
  **T stage**                                                                                                           \<0.001
  Tis,T0,T1,T2 (0,1, 2,3)      3,961       568              13.2     1,854             12.9     1,539            13.2   
  T3-T4 (4,5)                  18,759      2,878            66.8     9,207             64       6,674            57.3   
  Unknown                      7,613       863              20       3,322             23.1     3,428            29.4   
  **N stage**                                                                                                           \<0.001
  N0                           9,607       1,116            25.9     4,382             30.5     4,109            42.8   
  N1                           9,569       1,506            35       4,817             33.5     3,246            27.9   
  N2                           7,760       1,306            30.3     3,761             26.1     2,693            23.1   
  Unknown                      3,397       381              8.8      1,423             9.9      1,593            13.7   
  **Diagnosed methods**                                                                                                 \<0.001
  Biopsy                       28,822      4,241            98.4     14,002            97.4     10,579           90.9   
  Other method                 1,511       68               1.6      381               2.6      1062             9.1    
  **Pathology type**                                                                                                    \<0.001
  Adenocarcinoma               25,850      3,749            87       12,655            88       9,446            81.1   
  Mucinous                     2,558       429              10       1,157             8        972              8.3    
  Other type                   1,248       115              2.7      441               3.1      692              5.9    
  Unspecified                  677         16               0.4      130               0.9      531              4.6    
  **Pathology grade**                                                                                                   \<0.001
  Well differentiated          1,204       165              3.8      586               4.1      453              3.9    
  Moderately differentiated    15,152      2.308            53.6     7,527             52.3     5,317            45.7   
  Poorly differentiated        5,924       918              21.3     2,767             19.2     2,239            19.2   
  Undifferentiated             1,167       172              4        526               3.7      469              4      
  Unknown                      6,886       746              17.3     2,977             20.7     3,163            27.2   
  **Positive lymph nodes**                                                                                              \<0.001
  0                            15,012      1,885            43.7     6,917             48.1     6,210            53.3   
  1-3                          415         63               1.5      183               1.3      169              1.5    
  \>4                          14,472      2,293            53.2     7,060             49.1     5,119            44     
  Unknown                      434         68               1.6      223               1.6      143              1.2    
  **Number of Lymph node**                                                                                              \<0.001
  0                            3,286       471              10.9     1,664             11.6     1,151            9.9    
  \<12                         10,192      1,613            37.4     4,948             34.4     3,631            31.2   
  \>=12                        1,763       327              7.6      829               5.8      607              5.2    
  Unknown                      15,092      1,898            44       6,942             48.3     6252             53.7   
  **Tumor site**                                                                                                        \<0.001
  RCC                          12,452      1,171            27.2     5,294             36.8     5,987            51.4   
  LCC                          8,797       1,550            36       4,331             30.1     2,916            25.0   
  RSC                          9,084       1,588            36.9     4,758             33.1     2,738            23.5   
  **Tumor sizes**                                                                                                       \<0.001
  \<=40 mm                     6,649       1,002            23.3     3,159             22       2,488            21.4   
  40-70 mm                     9,867       1,442            33.5     4,803             33.4     3,622            31.1   
  \>=70 mm                     4,341       656              15.2     2,124             14.8     1,561            13.4   
  Unknown                      9,476       1,209            28.1     4,297             29.9     3,970            34.1   
  ---------------------------- ----------- ---------------- -------- ----------------- -------- ---------------- ------ -------------

Abbreviations, RCC, right-sided colon cancer; LCC, left-sided colon cancer; RSC, rectosigmoid cancer.

Significant differences among the patient cohorts included race, tumor size, T stage, N stage, tumor location, degree of differentiation, and histological type (P\< 0.001,respectively). Generally, the younger and middle-aged patients had larger tumors, advanced T stage, advanced N stage, more adenocarcinoma, and more moderate differentiation than the older patients did (P\< 0.001).

Regarding to tumor location, the proportion of metastases were significantly different among age groups, for example, in RCC subgroup, the proportions were 27.2% in the younger cohort, 36.8% in the middle-age cohort, and 51.4% in the older-aged cohort. It indicated that the older patients with RCC had likely more metastases than the other groups. The younger and middle-aged patients had a significantly higher rate of surgery compared to their older counterparts (P\< 0.001). The results may be attributed to their better physical condition to withstand the treatment. Specifically, African-American patients tended to have metastatic colorectal cancer at an older age (72.6%, 62.9%, and 55.7% in the older, middle-aged, and younger groups, respectively, P\< 0.001). In contrast, White patients tended to be diagnosed with metastasis at a younger age (15.9%, 16.9%, and 8.3% in the younger, middle aged, and older groups, respectively).

Different metastatic patterns of colorectal cancer in patients by age group
---------------------------------------------------------------------------

Many patients developed metastatic diseases in more than one site. [Table 2](#t2){ref-type="table"} summarizes all possible combinations of four sites of metastases. We found the liver was the most common site of metastasis for colorectal cancer and accounted for more than half of all the sites in the three age groups ([Table 2](#t2){ref-type="table"}).

###### The proportions of metastatic patterns in different age groups.

  ----------------------------- ----------- -------- ---------------- -------- ----------------- -------- ---------------- ------ -------------
  **Patient characteristics**   **Total**            **\<50 years**            **50-69 years**            **\>69 years**          **P value**
  **No**                        **%**       **No**   ***%***          **No**   ***%***           **No**   ***%***                 
  **Total**                     30,333               4,309            14.2     14,383            47.4     11,641           38.4   
  **One site**                  18,833      62.1     2,690            62.4     8,901             61.9     7,242            62.2   \<0.001
  Bone only                     327         1.1      53               1.2      141               1        133              1.1    
  Lung only                     1,913       6.3      219              5.1      820               5.7      1,874            16.1   
  Liver only                    16,478      54.3     2.405            55.8     7,880             54.8     5,193            44.1   
  Brain only                    115         0.4      13               0.3      60                0.4      42               0.4    
  **Two sites**                 5,367       17.7     694              16.1     2,709             18.8     1,964            16.9   0.158
  Lung and liver                4,480       14.8     578              13.4     2254              15.7     1648             14.2   
  Lung and bone                 136         0.4      24               0.6      58                0.4      215              1.8    
  Lung and brain                55          0.2      4                0.1      29                0.2      24               0.2    
  Liver and bone                620         2        82               1.9      58                0.4      54               0.5    
  Liver and brain               74          0.2      5                0.1      45                0.3      24               0.2    
  Bone and brain                2           0.1      1                0.1      0                 0        1                0.1    
  **Three sites**               622         2.1      75               1.7      356               2.5      191              1.6    0.526
  Lung, Liver and bone          501         1.7      59               1.4      279               1.9      163              1.4    
  Lung, Liver and brain         89          0.3      11               0.3      57                0.4      21               0.2    
  Liver, bone and brain         19          0.1      3                0.1      13                0.1      3                0.1    
  Lung, bone and brain          13          0,1      2                0.1      7                 0.1      4                0.1    
  **Four sites**                                                                                                                  
  Liver, lung, bone and brain   31          0.1      2                0.1      21                0.1      8                0.1    
  **Other sites**               5480        18.1     848              19.7     2396              16.7     2236             19.2   
  ----------------------------- ----------- -------- ---------------- -------- ----------------- -------- ---------------- ------ -------------

Patients with multiple organ metastases had fewer treatment options and tended to have poorer outcomes. Unfortunately, at least 19.8% of all the cases had multiple organ metastases. The most common combination of organs with metastases was the liver and lung, which comprised 14.8% of patients with the multiple organ metastases. Only 31(0.1%) patients had metastases to all four sites ([Table 2](#t2){ref-type="table"}).

Significant differences in the rates of one site metastasis were found between the three age groups (P\< 0.001). The older group tended to have more single lung metastasis (16.1%, 5.7%, and 5.1% in the older, middle-aged, and younger groups, respectively) and the younger group tended to have more single liver metastasis (44.1%, 54.8%, and 55.8% in the older, middle-aged, and younger groups, respectively). However, no differences were found in the rate of metastases to two (P = 0.158) or three sites (P = 0.526).

Comparisons of OS
-----------------

Substantive differences were found in overall survival (OS) (P\< 0.001) between the three age groups ([Figure 1](#f1){ref-type="fig"}). The older group had the worst survival with a median survival time (MST) of 6 months. The results of the survival analysis of the subgroups by tumor location ([Figure 1](#f1){ref-type="fig"}) showed that the prognoses of patients with left-sided colon cancer (LCC) and recto-sigmoid cancer (RSC) worsened with increased age. The middle-aged and the younger groups with RCC had longer MSTs than the older group. However, the younger group's prognosis was not as good as the middle-aged patients in the RCC group were (P \>0.05).

![**Comparisons of survival of patients with metastasic colorectal cancer (mCRC).** (**A**) The entire cohort; (**B**) Right-sided colorectal cancer (RCC) subgroup; (**C**) Left-sided colorectal cancer (LCC) subgroup; (**D**) Rectosigmoid cancer (RSC) subgroup.](aging-10-101700-g001){#f1}

We also found that patients who underwent surgery of the primary site or radiotherapy had better survival, indicating potential benefits from regional treatment for metastatic patients ([Figure 2A](#f2){ref-type="fig"}, P\< 0.001). The benefits observed in the subgroups are shown in [Figure 2 B-D](#f2){ref-type="fig"} P\< 0.001.

![**Comparisons of the benefits of surgery for patients with metastatic colorectal cancer (mCRC)**. (**A**) The entire cohort; (**B**) \<50 years old subroup; (**C**) 50-69 years old subgroup; (**D**) \>69 years old subgroup.](aging-10-101700-g002){#f2}

The results of the univariate analysis and multivariate Cox regression, which were conducted to evaluate the independent factors for OS are presented in [Table 3](#t3){ref-type="table"}. The univariate analysis showed that all the factors included in the study were associated with OS. The significant factors were then included in the multivariate analysis and all of the factors, except for marital status (P = 0.061), were associated with OS (P\< 0.05). As shown in [Table 3](#t3){ref-type="table"}, age at diagnosis was an independent prognostic factor for patients with mCRC. Compared to the younger patients, the middle-aged patients had worse OS (HR: 1.389, 95% CI: 1.230--1.351, P \< 0.001) and the older patients had the worst OS (HR: 2.141, 95% CI: 2.041--2.247, P \< 0.001).

###### Univariate and multivariate analyses of overall survival.

  Patient characteristics       **Univariate analysis**                 **Multivariate analysis**   
  ----------------------------- ------------------------- ------------- --------------------------- -------------
  **OS**                                                  **OS**                                    
                                **HRs (95%CI)**           **P-value**   **HRs (95%CI)**             **P-value**
  **Sex**                                                                                           
  Female vs Male                1.042 (1.014-1.072)       0.004         0.943 (0.916-0.971)         \<0.001
  **Age group**                                           \<0.001                                   \<0.001
  \<50                          Reference                               Reference                   
  50-69                         1.334 (1.273-1.398)       \<0.001       1.389 (1.230-1.351)         \<0.001
  \>69                          2.428 (2.317-2.545)       \<0.001       2.141 (2.041-2.247)         \<0.001
  **Married**                                             \<0.001                                   0.061
  Unmarried                     Reference                               Reference                   
  Married                       1.180 (1.115-1.311)       \<0.001       1.138 (1.109-1.168)         \<0.001
  Unknown                       0.867 (0.845-0.890)       \<0.001       0.908 (0.885-0.932)         \<0.001
  **Race**                                                                                          \<0.001
  Black                         Reference                               Reference                   
  White                         1.072 (1.030-1.115)       0.001         1.099 (1.055-1.144)         \<0.001
  Hispanic                      0.895 (0.855-0.938)       \<0.001       1.001 (0.955-1.050)         0.953
  Asian/Pacific Islander        0.862 (0.816-0.911)       \<0.001       0.944 (0.893-0.998)         0.041
  Native American               1.042 (0.899-1.222)       0.612         1.262 (1.075-1.480)         0.004
  Unknown                       0.575 (0.371-0.892)       0.013         0.740 (0.477-1.148)         0.179
  **Surgery**                                             \<0.001                                   \<0.001
  No                            Reference                               Reference                   
  Yes                           0.472 (0.458-0.485)       \<0.001       0.694 (0.641-0.752)         \<0.001
  Unknown                       0.835 (0.629-1.109)       0.214         0.837 (0.629-1.113)         0.220
  **T stage**                                             \<0.001                                   \<0.001
  Tis,T0,T1,T2 (0,1, 2,3)       Reference                               Reference                   
  T3-T4 (4,5)                   0.737 (0.706-0.769)       \<0.001       1.051 (1-1.105)             \<0.001
  Unknown                       1.442 (1.377-1.510)       \<0.001       1.080 (1.030-1.134)         0.002
  **N stage**                                             \<0.001                                   \<0.001
  N0                            Reference                               Reference                   
  N1                            0.775 (0.748-0.804)       \<0.001       0.900 (0.862-0.940)         \<0.001
  N2                            0.826 (0.796-0.857)       \<0.001       1.083 (1.021-1.149)         0.008
  Unknown                       1.570 (1.501-1.642)       \<0.001       1.1080 (1.030-1.133)        0.002
  **Diagnosed methods**                                                                             
  Other method vs Biopsy        3.345 (3.163-3.537)       \<0.001       1.401 (1.297-1.513)         \<0.001
  **Pathology type**                                      \<0.001                                   \<0.001
  Adenocarcinoma                Reference                               Reference                   
  Mucinous                      1.163 (1.107-1.222)       \<0.001       1.154 (1.097-1.215)         \<0.001
  Other type                    2.507 (2.356-2.669)       \<0.001       1.489 (1.390-1.595)         \<0.001
  Unspecified                   4.422 (4.079-4.793)       \<0.001       1.761 (1.588-1.953)         \<0.001
  **Pathology grade**                                     \<0.001       1.401 (1.297-1.513)         \<0.001
  Well differentiated           Reference                               1.000                       
  Moderately differentiated     0.969 (0.897-1.047)       0.426         1.081 (1-1.168)             0.050
  Poorly differentiated         1.542 (1.424-1.671)       \<0.001       1.602 (1.477-1.737)         \<0.001
  Undifferentiated              1.594 (1.441-1.764)       \<0.001       1.748 (1.577-1.937)         \<0.001
  Unknown                       1.989 (1.837-2.153)       \<0.001       1.246 (1.148-1.351)         \<0.001
  **Positive lymph nodes**                                \<0.001                                   \<0.001
  0                             Reference                               Reference                   
  1-3                           0.667 (0.592-0.751        \<0.001       1.324 (1.137-1.542)         \<0.001
  \>4                           0.480 (0.467-0.495)       0.791         0.792 (0.713-0.881)         \<0.001
  Unknown                       0.648 (0.577-0.728)       \<0.001       0.902 (0.794-1.024)         0.110
  **Number of Lymph node**                                \<0.001                                   \<0.001
  0                             Reference                               Reference                   
  \<12                          1.408 (1.330-1.491)       \<0.001       1.356 (1.264-1.456)         \<0.001
  \>=12                         2.194 (2.035-2.365)       \<0.001       1.764 (1.608-1.935)         \<0.001
  Unknown                       2.849 (2.698-3.009)       \<0.001       1.541 (1.379-1.721)         \<0.001
  **Tumor site**                                          \<0.001                                   \<0.001
  RCC                           Reference                               Reference                   
  LCC                           0.715 (0.691-0.739)       \<0.001       0.805 (0.777-0.834)         \<0.001
  RSC                           0.706 (0.683-0.730)       \<0.001       0.642 (0619-0.666)          \<0.001
  **Tumor sizes**                                         \<0.001                                   \<0.001
  \<=40 mm                      Reference                               Reference                   
  40-70 mm                      1.147 (1.101-1.194)       \<0.001       1.116 (1.071-1.162)         \<0.001
  \>=70mm                       1.384 (1.318-1.453)       \<0.001       1.274 (1.213-1.338)         \<0.001
  Unknown                       1.857 (1.785-1.932)       \<0.001       1.163 (1.112-1.216)         \<0.001
  **Metastasis organ number**                             \<0.001                                   
  1                             Reference                               Reference                   
  2                             2.413 (1.642-3.546)       \<0.001       2.281 (1.551-3.353)         \<0.001
  3                             1.481 (1.428-1.535)       \<0.001       1.274 (1.228-1.322)         \<0.001
  4                             2.049 (1.873-2.241)       \<0.001       1.680 (1.535-1.839)         \<0.001
  Other organ metastasis        0.958 (0.923-0.996)       0.029         0.905 (0.869-0.941)         \<0.001

Abbreviations, OS, overall survival; RCC, right-sided colon cancer; LCC, left-sided colon cancer; RSC, Rectosigmoid cancer.

HRs: hazard ratios; CI: confidence interval.

Comparisons of survival between patients with single and multi-site metastatic colorectal cancer
------------------------------------------------------------------------------------------------

We compared the effects of CRC metastases to single and multiple distant organs on the MST of the study population. The results indicated that there were significant differences in OS among the patients with different specific metastatic sites ([Figure 3](#f3){ref-type="fig"}). No survival difference was found between patients with metastases to three or four sites (P = 0.335, [Figure 3A](#f3){ref-type="fig"}). This survival difference between subgroups is shown in [Figure 3B-D](#f3){ref-type="fig"}. However, no survival difference was found between patients with metastases to two or three sites in the younger group (P = 0.061). Among the patients in the middle-aged group, no survival difference was found between those with single site metastasis and metastasis to other sites (P = 0.516).

![**Comparisons of survival among patients with metastatic colorectal cancer (mCRC) with single or multi-site metastases.** (**A**) The entire cohort; (**B**) \< 50 years old subgroup; (**C**) 50-69 years old subgroup; (**D**) \>69 years old subgroup.](aging-10-101700-g003){#f3}

Among the patients with single site metastasis, those with lung metastasis only, had a significantly longer survival compared to the other metastatic patients (MST = 18 months, [Table 4](#t4){ref-type="table"}). Patients with liver invasion only, had a similar intermediate MST of 15 months. However, the brain metastasis only group (MST = 6 months) and bone metastasis only group (MST = 6 months) had the poorest prognosis compared to the other groups. Among the patients with multi-site metastases, those with lung and liver metastasis had the best survival (MST = 10 months) and patients with lung and bone metastasis had intermediate length of survival (MST = 8 months). However, the survival of the patients with other combinations of sites was very poor and no significant differences were found.

###### The survival analyses of metastatic patterns in different age groups.

  ----------------------------- ------------------ ------------------ ------------------ ----------------- -------------
  **Patient characteristics**   **Total**          **\<50 years**     **50-69 years**    **\>69 years**    **P value**
  **MST (mo)**                  **MST (mo)**       **MST (mo)**       **MST (mo)**                         
  **Total**                     13 (12.69-12.3)    23 (22.08-23.92)   17 (16.51-17.49)   6 (5.7-6.3)       \<0.001
  **One sites**                 15 (14.57-15.43    25 (22.38-26.25)   20 (19.33-20.67    7 (6.6-7.4)       \<0.001
  Bone only                     6 (4.55-7.44)      12 (8.49-15.51)    10 (6.08-13.92)    2 (1.12-2.88)     \<0.001
  Lung only                     18 (16.58-19.41)   30 (25.77-34.23)   25 (21.40-28.6)    10 (8.26-11.64)   \<0.001
  Liver only                    15 (14.55-15.45)   25 (23.74-26.26)   20 (19.31-20.69)   7 (6.59-7.41)     \<0.001
  Brain only                    6 (4.18-7.8)       13 (1.88-24.12)    8 (5.23-10.77)     4 (2.06-5.94)     \<0.001
  **Two sites**                 9 (8.46-9.54)      16 (14.55-17.45)   12 (11.21-12.79)   4 (3.58-4.42)     \<0.001
  Lung and liver                10 (9.37-10.63)    17 (15.28-18.73)   13 (12.1-13.9)     4 (3.52-4.84)     \<0.001
  Lung and bone                 8 (5.27-10.73)     13 (2.34-23.66)    10 (6.08-13.92)    4 (2.28-5.73)     0.001
  Liver and bone                5 (3.9-6.08)       10 (7.62-12.38)    10 (6.08-13.92)    3 (2.46-3.54)     \<0.001
  Lung and brain                4 (1.2-6.78)       8 (3.42-11.21)     7 (3.96-10.04)     2 (1.31-2.69)     0.062
  Liver and brain               3 (1.33-4.67)      5 (1.08-8.92)      3 (1.84-4.17)      1 (0.04-1.96)     0.079
  Bone and brain                4                  4                                     7                 0.317
  **Three sites**               3 (1.7-4.3)        12 (7.7-16.3)      5 (3.91-6.09)      2 (0.15-3.85)     \<0.001
  Lung, Liver and bone          5 (3.92-6.08)      12 (6.88-17.12)    5 (3.8-6.1)        3 (2.17-3.83)     \<0.001
  Lung, Liver and brain         6 (3.54-8.46)      8 (5.51-10.45)     6 (4.5-7.49)       2 (0.27-3.73)     0.081
  Liver, bone and brain         3 (1.1-8.17)       3 (1.2-6.2)        6 (3.2-8.79)       1                 0.060
  Lung, bone and brain          3 (1.33-4.67)      6                  3 (1.83-4.17)      1                 0.999
  **Four sites**                                                                                           
  Liver, lung, bone and brain   3 (1-8.17)         12 (8.64-10.34)    3 (1.2-7)          2 (0.15-3.85)     0.420
  **Other sites**               15 (1.24-15.76)    27 (24.01-29.99)   19 (17.67-20.33)   8 (7.14-8.86)     \<0.001
  ----------------------------- ------------------ ------------------ ------------------ ----------------- -------------

Abbreviations, MST, median survival time.

The prognoses of patients in the three age groups with the same metastatic patterns were analyzed and the results showed that their prognoses worsened with increased age among the patients with single site metastasis. Among the patients with multiple metastases, those in the younger and middle-aged groups had better survival than the patients in the older group when brain metastasis was not involved. In other words, when patients with multiple metastases had brain metastasis, there were no survival differences among the three age groups.

DISCUSSION
==========

This large-scale study provided more in-depth knowledge and a better understanding of the heterogeneity of colorectal cancer among different age groups. We found that a younger age at diagnosis was associated with being White, having advanced N stage, more lymph node involvement, and a tendency to have LCC. Patients in the younger age group were more likely to have single liver metastasis, but less likely to have single lung metastasis compared with patients in the older age group, and the younger patients had better survival when brain metastasis was not involved.

The most common site of CRC metastasis is the liver, which is consistent with the results of a previous study \[[@r14]\], and the mechanism is thought to be multifaceted. First, the "seed and soil hypothesis" may partially account for the phenomenon of different metastatic patterns \[[@r15]\]. It seems that tumor cells from different subpopulations have favored microenvironments in distant organs, which facilitate their optimal invasion and proliferation in these organs. Second, a study revealed that neutrophils contribute to the colonization of breast cancer cells in the lung \[[@r16]\]. The existence of a similar mechanism for circulating tumor cells in the metastasis of CRC to the liver should be studied further. Third, previous evidence indicates that venous drainage of the colon to the portal system might be a potential mechanism underlying the metastatic pattern of CRC to the liver, first, and then to the lungs \[[@r17],[@r18]\]. The underlying molecular mechanisms need further investigation to yield findings that may be used for cancer prevention.

Consistent with previously published reports \[[@r19]-[@r21]\], this study revealed a significant difference in OS between patients in the older age group and their younger counterparts. Age at diagnosis was one of the independent prognostic factors in the study population. The MST was 23 months for the younger patients and 17 and 6 months for the middle-aged and older groups, respectively, which may have a multi-factorial explanation. Many age-related factors, such as lower immune response \[[@r22]\], and higher levels of chronic inflammation \[[@r23]\] may influence survival of metastasis. Hu et al., reported that patients younger than 50 years have a better chance than those older than 50 years of receiving chemotherapy, radiation therapy, and surgery \[[@r24],[@r25]\]. However, elderly patients are less likely to receive optimal treatment because of age-related increases in the deterioration of organ function or comorbidities \[[@r26]\]. Attenuation of the immune system has also been reported to influence (i.e., worsen) survival in older adults with mCRC.

Interestingly, the survival time of the younger group of patients with RCC was similar to that of the middle-aged patients. Other studies have suggested differences in terms of genetics, biology, and demographics between tumor locations of CRC; RCC was more common for both the older groups \[[@r27],[@r28]\]. A recent molecular subtype analysis of CRC patients showed that the "type 5" group (MSI-high, BRAF-and KRAS-mutation negative, non-CpG isl and methylator phenotype) was present in a significant portion of patients aged \< 40 years and 40--49 years (10% and 20%, respectively) \[[@r29]\].

Additionally, younger patients presented with metastatic disease at the time of diagnosis more often than did older patients. This may be because RCC is more likely to be classified as a mucinous adenocarcinoma (MC) in older adults \[[@r27],[@r28]\], and MC has been reported to be more frequent than adenocarcinoma (AC) in presentations of multi-metastatic diseases \[[@r5]\]. The poor prognosis of the RCC patients with metastatic disease might have been due the fact that curative surgery is often limited to patients with liver metastasis \[[@r11],[@r30]\]. This might have led to the similar survival times of the younger and the middle-aged groups with RCC. Nevertheless, there might have been other underlying factors. More importantly, we found that patients with different metastatic patterns had different survival outcomes. Specifically, the liver metastasis only group had the longest MST compared to the other patients with metastases, whereas the brain metastasis only group and the multi-site metastases group had the poorest outcomes. Despite their large numbers, neither clinical trials nor germinate immunotherapy-based treatments have shown significant improvements in patients with metastases \[[@r31],[@r32]\]. Unfortunately, therapies are limited for patients with brain metastasis (mainly because of the blood-brain barrier) and multi-site metastases \[[@r33]\]. These results call for greater efforts to improve precision in medicine for the prevention and treatment of CRC metastasis on an individual basis.

This study has some limitations. We could not collect detailed information about the patients' treatment, such as surgical procedures, chemotherapy regimens, or radiation methods from the SEER database, which may be a confounding factor in the results. Several other factors, other than age at diagnosis, might have also influenced the survival time of patients with mCRC. Therefore, the results need further validation in future studies.

CONCLUSION
==========

Our research summarized the tumor characteristics and survival outcomes of patients in three age groups with mCRC from a large sample of the population. Age was a robust prognostic factor and patients in the younger age group were more likely to have single liver metastasis, but less likely to have single lung metastasis compared with the patients in the older age group. The younger patients had better survival when their cancer did not involve brain metastasis. To determine more appropriate healthcare for aging patients with mCRC, further investigations of biochemical and molecular changes with aging are required.

MATERIALS AND METHODS
=====================

Data were retrieved from the SEER database between 2010 and 2014. The datasets, which are available in the SEER dataset repository at: <https://seer.cancer.gov/>, represented 30% of the United States population. Pathology was classified as adenocarcinoma (AC), mucinous adenocarcinoma (MC), or other. Grade was defined as well differentiated, moderately differentiated, and poorly differentiated, or undifferentiated. Tumor location and their anatomical components, including RCC were classified as follows: RCC (cecum, ascending colon, hepatic flexure, and transverse colon), LCC (splenic flexure, descending colon, and sigmoid colon), RSC (recto-sigmoid junction and rectum), and appendix cancer \[[@r34]\]. Race/ethnicity was categorized as previously described \[[@r35]\]. The SEER 18 dataset categorized ethnicity as White, African-American, Native American/Alaskan Native, Asian/Pacific Islander, and unknown. The presence of bone, lung, liver, and brain metastases at diagnosis were available in the SEER database and were categorized as the number of metastases among the patients in our study. Patients were observed after the first diagnosis of CRC until the last follow-up, death, or end of the study, whichever occurred first.

Statistical analysis
--------------------

The Chi square test was used for the comparisons of categorical variables and the Kaplan-Meier method was used to estimate survival differences between the subgroups. Univariate and multivariable Cox regression analyses were performed to identify covariates associated with poor survival. All statistical tests were two-tailed and P\< 0.05 was considered statistically significant. Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA).

Assessing locus of control
--------------------------

Women completed a condensed version of the Adult Nowicki Strickland Internal External control scale (ANSIE) \[[@r24]\] in questionnaires administered at mean ages 30 and 48 years. The original ANSIE comprises 40 items in a yes/no format, which assess perceived control. The version used in the present study comprises 12 of the original 40 items, which were chosen after factor analysis of the ANSIE administered as a pilot to

Availability of data and material
---------------------------------

All data were retrieved from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute between 2010 and 2014. The datasets are available in the SEER dataset repository <https://seer.cancer.gov/>.
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